|
Diseases | Effect on target cells or animal models | References |
|
Psoriasis | KC: to enhance chemokine expression and cell proliferation | [22, 65] |
Murine model: to induce immune cell infiltrates in lesional skin |
AD | KC: to increase TNF-α expression and induce apoptosis | [28, 65] |
Dermal fibroblast: to regulate chemokine expression |
Murine model: to induce cellular infiltrates, migration of immune cells, and chemokine expression |
Cutaneous vasculitis | HMEC: to regulate NF-κB activation and chemokine production | [71, 92] |
Murine model: to induce endothelial damage and perivascular leukocyte infiltrates |
HPV infection | KC: to enhance TNFR2 expression and cell proliferation | [64] |
Carcinogenesis | Various tumor cells: to induce cell proliferation or apoptosis in a cytokine-dependent way | [64, 112, 113] |
Glioma cells: to promote cell migration and invasion |
KC: to induce cell proliferation |
Vascular ECs: to upregulate FGF-2 and VEGF-A expression and to promote angiogenesis |
Cutaneous lupus erythematosus | KC: to enhance Ro52 and proinflammatory cytokine expression and induce apoptosis | [70, 109] |
Macrophage: to enhance chemoattraction and cytokine expression (including TWEAK) |
MRL/lpr mice: to induce chemokine production, cell infiltration, and apoptosis |
Systemic sclerosis | Monocytes/macrophages: to lead to greater extent of skin fibrosis or to exert as a protective role against fibrosis | [111, 114] |
Polymyositis & dermatomyositis | Myoblast: to induce degradation of myosin heavy chain, to affect cell proliferation and differentiation, and to induce metabolic abnormalities | [107, 115, 116] |
Murine model: to induce muscle atrophy and interstitial fibrosis |
Bullous pemphigoid | KC: to reduce BP180 expression and suppresses cell adhesion | [8] |
|